Table 2. Relationship between the proportion of CD19+ B cells and its subset in PBMCs and the clinicopathological parameters of IBCa patients.
| Variables | All cases | B cells | ||
|---|---|---|---|---|
| CD19+ | CD19+CD24+CD38+ | CD19+CD24+CD38+PD-L1+ | ||
| IDCa | 98 | |||
| Grade | ||||
| G1 | 14 | 5.32 ± 3.21 | 9.78 ± 5.41 | 82.88 ± 20.54 |
| G2 | 63 | 5.17 ± 3.15 | 11.83 ± 6.18 | 83.09 ± 21.06 |
| G3 | 21 | 5.26 ± 3.18 | 9.50 ± 3.69 | 86.69 ± 12.63 |
| P | 0.985 | 0.178 | 0.751 | |
| LN metastasis | ||||
| No | 48 | 5.33 ± 3.60 | 11.60 ± 6.84 | 81.30 ± 21.63 |
| Yes | 50 | 5.28 ± 2.85 | 10.40 ± 4.34 | 86.08 ± 16.69 |
| P | 0.931 | 0.303 | 0.223 | |
| TNM | ||||
| I | 24 | 4.74 ± 2.23 | 10.61 ± 5.69 | 87.30 ± 9.37 |
| II | 41 | 5.49 ± 3.92 | 11.07 ± 6.56 | 76.53 ± 26.35 |
| III | 24 | 5.79 ± 3.00 | 11.48 ± 4.67 | 88.30 ± 9.73 |
| IV | 9 | 4.85 ± 2.72 | 10.31 ± 4.66 | 94.88 ± 4.72 |
| P | 0.700 | 0.939 | 0.011 | |
| ER | ||||
| Negative | 32 | 6.36 ± 4.14 | 11.23 ± 6.98 | 82.28 ± 20.35 |
| Positive | 66 | 4.79 ± 2.56 | 10.87 ± 5.03 | 84.44 ± 18.92 |
| P | 0.056 | 0.773 | 0.605 | |
| PR | ||||
| Negative | 56 | 5.39 ± 3.61 | 10.67 ± 6.17 | 82.79 ± 20.31 |
| Positive | 42 | 5.19 ± 2.66 | 11.41 ± 5.06 | 84.99 ± 18.08 |
| P | 0.759 | 0.531 | 0.580 | |
| HER2 | ||||
| Negative | 62 | 5.54 ± 3.17 | 10.69 ± 6.12 | 83.61 ± 17.05 |
| Positive | 36 | 4.90 ± 3.32 | 11.50 ± 4.95 | 83.96 ± 22.97 |
| P | 0.345 | 0.501 | 0.930 | |
| Age | ||||
| <49 y | 39 | 5.30 ± 3.72 | 12.13 ± 6.84 | 82.25 ± 23.48 |
| ≥49 y | 59 | 5.31 ± 2.89 | 10.23 ± 4.73 | 84.72 ± 16.14 |
| P | 0.983 | 0.108 | 0.539 | |
| Tumor size | ||||
| <3 cm | 59 | 4.69 ± 3.03 | 11.09 ± 5.17 | 85.48 ± 18.81 |
| ≥3 cm | 39 | 6.24 ± 3.33 | 10.83 ± 6.50 | 81.21 ± 20.04 |
| P | 0.019 | 0.829 | 0.295 | |